Pharmafile Logo
Pharmafocus logo
Advanced Search

Biogen

Showing 15 posts of 117 posts found.

glenmark

FDA greenlights Glenmark’s generic version of Biogen’s Tecfidera in relapsing multiple sclerosis

October 7, 2020
Research and Development, Sales and Marketing Biogen, Glenmark, generic, multiple sclerosis

Glenmark Pharma will be celebrating after it secured FDA approval in the US to market dimethyl fumarate, a generic version …

News
biogen-idec-tecfidera-dimethyl-fumarate

Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute

August 20, 2020
Sales and Marketing Biogen, FDA, Mylan, generic, tecfidera

The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding authorisation to Mylan which is …

News
nhs_sign_8

Scottish Medicines Consortium approves new drugs in multiple sclerosis, ulcerative colitis and diabetes

April 15, 2020
Research and Development, Sales and Marketing Biogen, Fambyra, Janssen, NHS, Rimzoic, Sandoz, Sanofi, Scotland, Scottish Medicines Consortium, Stelara, Suliqua, pharma

Medical regulation must still continue even in a global pandemic, and the Scottish Medicines Consortium, (SMC) has ploughed on with …

News
biogen_austria_238

100 coronavirus cases linked to Biogen-hosted event in Boston, State of Massachusetts confirms

March 18, 2020
Manufacturing and Production, Medical Communications, Research and Development Biogen, coronavirus, pharma

It is now known that around 100 of the known cases of the COVID-19 coronavirus can be traced to an …

News
cambridge_skyline

Biogen and Takeda forced to send employees home as coronavirus hits Massachusetts

March 9, 2020
Manufacturing and Production, Medical Communications Biogen, Takeda, coronavirus, pharma

Big pharma has been hit by the coronavirus (COVID-19) outbreak right on its doorstep, as two of the biggest names …

News
shutterstock_274590824

Biogen stock surges following patent victory over Mylan for Tecfidera

February 6, 2020
Sales and Marketing Biogen, Mylan, multiple sclerosis, pharma, tecfidera

Biogen has emerged victorious in a patent dispute with Mylan relating to the latter’s multiple sclerosis therapy Tecfidera – a …

News
biogen_austria_238

Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal

January 14, 2020
Manufacturing and Production, Sales and Marketing Alzheimer's, Biogen, Pfizer, pharma

Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop …

News

Biogen terminates gosuranemab in progressive surpanuclear palsy following Phase 2 failure

December 16, 2019
Research and Development, Sales and Marketing Biogen, pharma, trial failure

Biogen has revealed its intention to shut down further development of gosuranemab after results of a Phase 2 study showed …

News
biogen_austria_238_29

Biogen scoops up eye and anti-TNF drug rights from Samsung Bioepis in $300m deal

November 7, 2019
Sales and Marketing Biogen, Samsung Bioepis, pharma

Biogen has struck a new deal with Samsung Bioepis, it has emerged, picking up the commercialisation rights to a raft …

News

FDA approves Biogen and Alkermes’ Vumerity for relapsing multiple sclerosis

October 30, 2019
Research and Development, Sales and Marketing Alkermes, Biogen, FDA, Vumerity, multiple sclerosis, pharma

The FDA has given the green light to Vumerity (diroximel fumarate), a novel oral fumarate developed by Biogen and Alkermes, …

News
biogen_austria_238

Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis

September 11, 2019
Research and Development Biogen, multiple sclerosis, pharma, tecfidera

Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period …

News

Four perspectives from life sciences companies on multichannel engagement

August 23, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Biogen, GSK, Lifesciences, Teva, healthcare, pharma

By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in …

News
shutterstock_212432119

Biogen & Alkermes’ multiple sclerosis drug proves “statistically superior” to Tecfidera at Phase 3

July 31, 2019
Research and Development Alkermes, Biogen, multiple sclerosis, pharma

Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s …

News

Biogen unveils promising new data for Spinraza in pre-symptomatic infants with spinal muscular atrophy

July 2, 2019
Manufacturing and Production, Research and Development Biogen, Spinraza, pharma, spinal muscular atrophy

Biogen has introduced new data on the efficacy of Spinraza in the treatment of pre-symptomatic infants in spinal muscular atrophy …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

June 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, EMA, Janssen, Orkambi, Pfizer

It was revealed this week that Pfizer suppressed findings that their anti-inflammatory Enbrel reduced the risk of Alzheimer’s by 64%. …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026